as 05-14-2024 4:00pm EST
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
Founded: | 2020 | Country: | United States |
Employees: | N/A | City: | WALTHAM |
Market Cap: | 282.6M | IPO Year: | 2021 |
Target Price: | $9.50 | AVG Volume (30 days): | 697.9K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.87 | EPS Growth: | N/A |
52 Week Low/High: | $0.98 - $5.20 | Next Earning Date: | 05-09-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | 116.68% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Adimab, LLC | IVVD | 10% Owner | Jan 19 '24 | Sell | $3.95 | 5,000,000 | $19,750,000.00 | 21,687,906 | SEC Form 4 |
IVVD Breaking Stock News: Dive into IVVD Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Insider Monkey
2 days ago
Simply Wall St.
3 days ago
GuruFocus.com
5 days ago
GlobeNewswire
6 days ago
GlobeNewswire
8 days ago
GlobeNewswire
12 days ago
GlobeNewswire
15 days ago